Guggenheim Maintains Buy on ProKidney, Raises Price Target to $7
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
Guggenheim analyst Vamil Divan maintains ProKidney (NASDAQ:PROK) with a Buy and raises the price target from $6 to $7.
Guggenheim analyst Vamil Divan maintains ProKidney (NASDAQ:PROK) with a Buy and raises the price target from $6 to $7.